Q-omics provides the consensus-scored NPM1P33 profile across patient tissues and cancer cell-line models. NPM1P33 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, NPM1P33 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, NPM1P33 RNA expression shows 11,759 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, LIHC, and UVM as cancer lineages where NPM1P33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P33 survival associations across molecular data types. NPM1P33 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P33 RNA expression–survival associations across cancer types. High NPM1P33 expression shows unfavorable associations in KIRP, PAAD, CESC, MESO and COAD, but favorable associations in LUSC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for NPM1P33 RNA expression.
This table summarizes NPM1P33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P33 shows higher tumor expression in LIHC, COAD, BRCA, KIRC, LUAD and THCA. The LIHC box plot shows higher NPM1P33 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p < 0.001).
This table shows molecular features associated with NPM1P33 in patient tissues and cancer cell lines. In patient samples, NPM1P33 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
